Core Insights - The company held an earnings briefing on September 19, 2025, to address investor inquiries regarding its business prospects and technological capabilities [1]. Group 1: Market Potential and Business Strategy - The brain-machine interface market is expected to grow significantly over the next three years, supported by technological advancements, demand from an aging population, and policy backing, although the company's future revenue contribution from this segment remains uncertain [2][4]. - The company emphasizes its core technology in multi-modal BioCV (biometric recognition and computer vision) and other advanced technologies, creating a competitive edge through a closed-loop system of technology, research, products, and market [2][3]. Group 2: Financial Performance - For the first half of 2025, the company reported a main revenue of 929 million yuan, a year-on-year increase of 2.9%, and a net profit attributable to shareholders of 93.24 million yuan, up 18.56% [5]. - The company's net profit growth outpaced revenue growth due to an increase in export sales, reduced sales expenses, and lower financial costs from exchange gains [3][5]. Group 3: International Operations and Product Development - 76% of the company's revenue comes from overseas markets, with significant growth in regions such as the Americas, Asia-Pacific, Middle East, and Europe, primarily from smart space technology products and solutions [3][5]. - The company is advancing its brain-machine interface business, focusing on emotion analysis, with a prototype expected to be launched by March 2026 [4].

Group 1: Market Potential and Business Strategy - The brain-machine interface market is expected to grow significantly due to technological advancements, aging population, and policy support, with a focus on sustainable development [2] - The company acknowledges uncertainties regarding future revenue contributions from the brain-machine business and advises investors to consider associated risks [2] - The company aims to deepen the integration of AI and BioCV core technologies to drive product innovation and implement a multi-brand strategy [3] Group 2: Financial Performance - The company's non-GAAP net profit growth rate has significantly outpaced revenue growth, primarily due to increased export ratios leading to higher gross margins and reduced sales expenses [3] - 76% of the company's revenue comes from overseas markets, with notable growth in the Americas, Asia-Pacific, Middle East, and Europe [3] Group 3: Technological Capabilities - The company has developed core technologies in brainwave detection, eye movement analysis, multimodal small model analysis, audio analysis, and facial micro-expression analysis for human-computer interaction [3] - The company is progressing with the development of a brain-machine interface product, focusing on emotion analysis, with a prototype expected by March 2026 [3] Group 4: Acquisition and Expansion Plans - The company is advancing its acquisition of Longzhiyuan and will provide updates through official announcements [3] - The construction of the manufacturing facility in Atlanta, USA, is currently underway [3]